{"id":11219,"date":"2026-11-06T18:11:53","date_gmt":"2026-11-06T12:41:53","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/emcure-share-price-today-2026-11-06\/"},"modified":"2026-11-06T18:11:55","modified_gmt":"2026-11-06T12:41:55","slug":"emcure-share-price-today-2026-11-06","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/emcure-share-price-today-2026-11-06\/","title":{"rendered":"Emcure Pharmaceuticals Share Price Today: Rises 11.95% in 3 Trading Sessions | 6 November 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: EMCURE<\/strong> \u00b7 6 November 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b92,212.80<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-1.43%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b92,253.20 \/ \u20b92,181.10<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b92,245.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>2.32 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>6 November 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Emcure Pharmaceuticals has risen 11.95% over 3 trading sessions; today&#x27;s move is -1.43%.<\/li>\n<li>Emcure Pharmaceuticals submitted its unaudited financial results for the quarter and half year ended September 30, 2026, reporting operating revenue of \u20b928,205 million, a 24.3% year-on-year increase. EBITDA grew by 30.9% to \u20b95,748 million with a margin of 20.4%, while profit after tax rose 29.3% to \u20b93,251 million. The company highlighted strong domestic performance led by women&#x27;s health, cardio-metabolics, and CNS segments, alongside international growth across Europe, Canada, and rest of world markets.<\/li>\n<li>Trading volume was 1.09 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Emcure Pharmaceuticals share price: 11.95% rise over 3 trading sessions<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Emcure Pharmaceuticals Ltd. (EMCURE) moved lower on November 6, 2026, declining by 1.43% to settle at \u20b92,212.80 compared to its previous close of \u20b92,245.00. The stock opened lower at \u20b92,181.70, touching a day&#x27;s low of \u20b92,181.10 and a high of \u20b92,253.20.<\/p>\n<p class=\"wt-copy\">The broader market and sectoral trend showed positive momentum during the session, contrasting with the stock&#x27;s pullback. The Nifty index gained 2.01%, while the Nifty Pharma sector benchmark advanced 1.21%. Despite the broader strength in pharmaceutical equities, Emcure experienced profit-taking following a strong recent rally, which included a return of 3.92% in the prior trading session and an 18.22% gain over the preceding five trading days.<\/p>\n<p class=\"wt-copy\">Company disclosures from earlier in November outline robust financial performance for the period ended September 30, 2026, featuring a 24.3% year-on-year increase in operating revenue to \u20b928,205 million and a 29.3% growth in profit after tax to \u20b93,251 million. Additionally, management announced plans to amalgamate wholly owned subsidiaries Zuventus Healthcare and Emcutix Biopharmaceuticals with the holding company, while noting regulatory income tax penalty orders totaling \u20b957,73,96,732 received in October 2026 for assessment years 2015-16 to 2021-22.<\/p>\n<p class=\"wt-copy\">2.32 lakh shares traded by 6 November 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 2.13 lakh shares (1.09 times). The five-day average daily volume was 5.80 lakh shares. Separately, the NSE report for 6 November 2026 showed 1.44 lakh shares delivered, representing 62.33% of that day\u2019s traded volume. The same report recorded 36,503 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>profit-taking after recent multi-day strength<\/strong><\/p>\n<p class=\"wt-copy\">The stock declined 1.43% despite broader market and sector gains, following a strong multi-day advance that included a 3.92% gain in the prior session and an 18.22% return over the preceding five days. No single same-day company catalyst was announced to trigger the move, pointing toward standard profit-taking.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Q2FY27 Financial Results and Investor Presentation<\/div>\n<div class=\"wt-card-date\">3 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Emcure Pharmaceuticals submitted its unaudited financial results for the quarter and half year ended September 30, 2026, reporting operating revenue of \u20b928,205 million, a 24.3% year-on-year increase. EBITDA grew by 30.9% to \u20b95,748 million with a margin of 20.4%, while profit after tax rose 29.3% to \u20b93,251 million. The company highlighted strong domestic performance led by women&#x27;s health, cardio-metabolics, and CNS segments, alongside international growth across Europe, Canada, and rest of world markets.<\/p>\n<p class=\"wt-copy\">Financial results and revenue growth metrics directly drive core valuation and institutional sentiment.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Scheme of Amalgamation for Subsidiaries<\/div>\n<div class=\"wt-card-date\">12 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The board of directors approved a proposed scheme of amalgamation for wholly owned subsidiaries Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited with the holding company, Emcure Pharmaceuticals Limited. The proposed restructuring remains subject to requisite statutory and regulatory approvals. Management aims to simplify the group holding structure and achieve operational synergies.<\/p>\n<p class=\"wt-copy\">Corporate restructuring actions affect corporate governance structures and backend operational efficiencies.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_12102026103306_OutcomeofBM12102026_Final.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Income Tax Department Penalty Orders Disclosure<\/div>\n<div class=\"wt-card-date\">3 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Emcure Pharmaceuticals disclosed the receipt of various orders from the Income-tax Department imposing an aggregate penalty of \u20b957,73,96,732 for Financial Year 2014-15 through Financial Year 2020-21. The company stated it is evaluating appropriate legal remedies, including filing an appeal before the relevant Appellate Authority.<\/p>\n<p class=\"wt-copy\">Regulatory penalty orders represent potential cash outflows and legal contingencies requiring ongoing monitoring.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_02102026213119_EPLReg30IntimationOrder.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">3 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_03112026134234_EPLOutcomeofBMQ2FY27.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Management \/ board update<\/div>\n<div class=\"wt-card-date\">12 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Emcure Pharmaceuticals Limited has informed the Exchange that the Board of Directors at the meeting held on October 12, 2026 have approved the proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries with Emcure Pharmaceuticals Limited &#8211; Holding Company, subject to requisite statutory and regulatory approvals.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_12102026103306_OutcomeofBM12102026_Final.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">77.82%<\/div>\n<div class=\"wt-note\">77.83% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">4.94%<\/div>\n<div class=\"wt-note\">4.88% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">13.43%<\/div>\n<div class=\"wt-note\">13.34% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741485_19102026034802_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 7.05% on 30 September 2026. This compares with 6.87% on 30 June 2026, a change of +0.18 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 23 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Kotak Midcap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">43.82 lakh shares \u00b7 2.31%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Aditya Birla Sun Life Mutual Fund &#8211; Aditya Birla Sun Life Elss Tax Saver Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">27.42 lakh shares \u00b7 1.45%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd-A\/C Nippon India Multi Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">22.58 lakh shares \u00b7 1.19%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741485_19102026034802_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Bc Investments Iv Limited<\/div>\n<div class=\"wt-card-date\">25 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 9.70 lakh shares \u00b7 \u20b91,817.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Bc Investments Iv Limited<\/div>\n<div class=\"wt-card-date\">25 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 9.70 lakh shares \u00b7 \u20b91,817.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Hdfc Standard Life Insurance Company Ltd<\/div>\n<div class=\"wt-card-date\">25 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 5.57 lakh shares \u00b7 \u20b91,817.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Aditya Birla Sun Life Mutual Fund<\/div>\n<div class=\"wt-card-date\">25 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 2.61 lakh shares \u00b7 \u20b91,817.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Progress and regulatory approvals regarding the proposed amalgamation of Zuventus Healthcare and Emcutix Biopharmaceuticals<\/li>\n<li>Legal developments and appeal filings concerning the Income-tax Department penalty orders<\/li>\n<li>Execution of international growth pipelines across Europe, Canada, and RoW non-ARV markets<\/li>\n<li>Sustained delivery volumes relative to the 20-day average volume benchmark<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/emcure-share-price-today-2026-11-04\/\">Emcure Pharmaceuticals Share Price Today: Rises 15.43% in 2 Trading Sessions | 4 November 2026 \u2014 4 November 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/emcure-share-price-today-2026-11-03\/\">Emcure Pharmaceuticals Share Price Jumps 10.00% Intraday, Closes 4.94% Higher | 3 November 2026 \u2014 3 November 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/emcure\/\">More Emcure Pharmaceuticals news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Emcure Pharmaceuticals company news?<\/h3>\n<p class=\"wt-copy\">Emcure Pharmaceuticals submitted its unaudited financial results for the quarter and half year ended September 30, 2026, reporting operating revenue of \u20b928,205 million, a 24.3% year-on-year increase. EBITDA grew by 30.9% to \u20b95,748 million with a margin of 20.4%, while profit after tax rose 29.3% to \u20b93,251 million. The company highlighted strong domestic performance led by women&#x27;s health, cardio-metabolics, and CNS segments, alongside international growth across Europe, Canada, and rest of world markets.<\/p>\n<h3>How strong was Emcure Pharmaceuticals\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">2.32 lakh shares traded, 1.09 times the 20-day average daily volume. The price and volume data are dated 6 November 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/emcure-share-price-today-2026-11-06\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/emcure-share-price-today-2026-11-06\/\"}, \"headline\": \"Emcure Pharmaceuticals Share Price Today: Rises 11.95% in 3 Trading Sessions | 6 November 2026\", \"description\": \"Emcure Pharmaceuticals has risen 11.95% over 3 trading sessions. Today it is 1.43% lower at \u20b92,212.80. See price context, volume and key company developments.\", \"datePublished\": \"2026-11-06T18:11:42.413499+05:30\", \"dateModified\": \"2026-11-06T18:11:42.413499+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Emcure Pharmaceuticals\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"EMCURE\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/11\/emcure-company-news-2026-11-06.jpg\"]}]}<\/script><!-- wt-article-record:{\"recent_news\":[{\"summary\":\"Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"03-Nov-2026 13:44:22\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_03112026134234_EPLOutcomeofBMQ2FY27.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Emcure Pharmaceuticals Limited has informed the Exchange that the Board of Directors at the meeting held on October 12, 2026 have approved the proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries with Emcure Pharmaceuticals Limited - Holding Company, subject to requisite statutory and regulatory approvals.\",\"category\":\"Amalgamation\/Merger\",\"date\":\"12-Oct-2026 10:33:18\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_12102026103306_OutcomeofBM12102026_Final.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5},{\"summary\":\"Emcure Pharmaceuticals Limited has informed the Exchange that Record date as September 04, 2026, for the purpose of Final Dividend for the financial year ended March 31, 2026, subject to approval of members.\",\"category\":\"Record Date\",\"date\":\"06-Aug-2026 15:19:08\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_06082026151835_IntimationAGMdateandRecorddate.pdf\",\"headline\":\"Shareholder-return \/ corporate action\",\"impact\":\"This affects shareholder returns or the share structure and can influence near-term investor interest.\",\"importance_score\":3,\"completeness_score\":5},{\"summary\":\"EMCURE: Emcure Pharmaceuticals Limited has informed the Exchange about change in composition of the Board of the Company.\",\"category\":\"General Updates\",\"date\":\"23-Sep-2026 18:20:53\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/EMCURE_23092026182025_EPLUpdateonAGMresolutions.pdf\",\"headline\":\"Company update\",\"impact\":\"This is a recent company development worth monitoring. It should not automatically be treated as the sole cause of today's price move.\",\"importance_score\":2,\"completeness_score\":4}],\"promoter_pledge\":{\"summary\":\"Smita Paresh Shah, part of the promoter group has pledged 60,000 Equity Shares of the Company during the Financial Year 2024-25 and the said equity shares continue to remain pledged as on March 31, 2026.\",\"events\":[{\"summary\":\"Smita Paresh Shah, part of the promoter group has pledged 60,000 Equity Shares of the Company during the Financial Year 2024-25 and the said equity shares continue to remain pledged as on March 31, 2026.\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"24-Jun-2026 17:18:15\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_sandeshc_23062026124540_45.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":77.82,\"public_pct\":22.18,\"fii_pct\":4.94,\"dii_pct\":8.49,\"mf_pct\":7.05,\"institutional_pct\":13.43,\"noninst_pct\":8.75,\"mf_scheme_count\":23,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Kotak Midcap Fund\",\"shares\":4381625,\"pct\":2.31},{\"name\":\"Aditya Birla Sun Life Mutual Fund - Aditya Birla Sun Life Elss Tax Saver Fund\",\"shares\":2742491,\"pct\":1.45},{\"name\":\"Nippon Life India Trustee Ltd-A\/C Nippon India Multi Cap Fund\",\"shares\":2257585,\"pct\":1.19}],\"period\":\"30-SEP-2026\",\"submission_date\":\"19-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741485_19102026034802_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":77.83,\"previous_fii_pct\":4.88,\"previous_dii_pct\":8.46,\"previous_mf_pct\":6.87,\"previous_institutional_pct\":13.34,\"previous_mf_scheme_count\":23,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Bc Investments Iv Limited\",\"side\":\"Sell\",\"quantity\":\"969730\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b9176.20 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Bc Investments Iv Limited\",\"side\":\"Sell\",\"quantity\":\"969729\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b9176.20 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Hdfc Standard Life Insurance Company Ltd\",\"side\":\"Buy\",\"quantity\":\"556954\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b9101.20 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Aditya Birla Sun Life Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"261420\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b947.50 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Hdfc Standard Life Insurnace\",\"side\":\"Buy\",\"quantity\":\"157949\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b928.70 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Alpha Alternatives Equity Absolute Return Fund\",\"side\":\"Buy\",\"quantity\":\"137593\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.00 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Bnp Paribas Financial Markets\",\"side\":\"Buy\",\"quantity\":\"137592\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.00 Cr\"},{\"deal_type\":\"Block\",\"date\":\"25 Jun, 2026\",\"party\":\"Axis Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"137591\",\"price\":\"1,817\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.00 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Emcure Pharmaceuticals has risen 11.95% over 3 trading sessions. Today it is 1.43% lower at \u20b92,212.80. See price context, volume and key company developments.<\/p>\n","protected":false},"author":1,"featured_media":11218,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Emcure Pharmaceuticals Share Price Today: Rises 11.95% in 3 Trading Sessions | 6 November 2026","_witty_meta_description":"Emcure Pharmaceuticals has risen 11.95% over 3 trading sessions. Today it is 1.43% lower at \u20b92,212.80. See price context, volume and key company developments.","_witty_primary_phrase":"Emcure Pharmaceuticals share price today","_witty_reason_label":"profit-taking after recent multi-day strength","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[404],"class_list":["post-11219","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-emcure"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=11219"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11219\/revisions"}],"predecessor-version":[{"id":11220,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11219\/revisions\/11220"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/11218"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=11219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=11219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=11219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}